The Benefits and Impact of Later In-Licensing Deals for Biopharma

Posted by |2020-03-17T02:14:10-07:00March 17th, 2020|

Biopharma firms are in-licensing candidates later according to an industry expert, who says the trend is impacting the contract development and manufacturing sector. In-licensing—the practice of paying for rights to develop and commercialize a product discovered by another company—is a widely used strategy in the biopharmaceutical industry. According to a recent report in Nature, the […]

UC San Diego Health Develops COVID-19 Test, Begins Testing Patients

Posted by |2020-03-16T03:30:08-07:00March 13th, 2020|

The UC San Diego Health System has developed a diagnostic test that can determine whether a patient has contracted the novel coronavirus in about eight hours. Developed under guidance that the FDA published roughly two weeks ago amid the severe shortage of tests for the viral illness, COVID-19, UCSD Health developed and validated an in-house […]

Repertoire Immune Taps Torque Top Exec, Biogen Vet John Cox as CEO

Posted by |2020-03-12T23:34:17-07:00March 12th, 2020|

Repertoire Immune Medicines, a Cambridge, MA-based biotech Flagship Pioneering formed by combining its companies Cogen Immune Medicines and Torque Therapeutics, named John Cox its CEO. Cox has been Torque’s chief executive since late 2019. Previously Cox was the CEO of Bioverativ (NASDAQ: BIIV), which he spun out from Biogen (NASDAQ: BIIB) in 2016 and oversaw […]

Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic

Posted by |2020-03-12T01:00:53-07:00March 12th, 2020|

Reuse and recycle is more than an environmental slogan. It’s also a succinct description of how cells deal with old or damaged proteins. Kymera Therapeutics is developing drugs that use this cyclical cellular process to treat disease, and it has raised $102 million to move into clinical testing next year. The Series C round of […]

Genmab Taps Bristol Myers Veteran Mancini as Chief Operating Officer

Posted by |2020-03-10T09:20:21-07:00March 10th, 2020|

Genmab (NASDAQ: GMAB) has appointed Anthony Mancini to serve as executive vice president and chief operating officer. Mancini is joining Copenhagen, Denmark-based Genmab from Bristol Myers Squibb (NYSE: BMY), where he is senior vice president and head of US innovative medicines. When he starts at Genmab on March 23, he will be based in New […]

Kala to Take Another Shot at FDA Approval With New Dry Eye Drug Data

Posted by |2020-03-09T16:14:55-07:00March 9th, 2020|

A Kala Pharmaceuticals dry eye disease drug that was rejected by the FDA is now being readied for another regulatory filing based on new data. Last August the FDA rejected a Kala (NASDAQ: KALA) product meant to temporarily relieve signs and symptoms of dry eye disease. On Monday the Watertown, MA-based biopharma announced preliminary results […]

Senti Biosciences Appoints Jose Iglesias as Its Chief Medical Officer

Posted by |2020-03-09T03:30:09-07:00March 6th, 2020|

Senti Biosciences named Jose Iglesias as its chief medical officer, tasked with overseeing the development of its cell and gene therapy product candidates for the treatment of solid and liquid tumors. Iglesias’s previous experience includes CMO and clinical development leadership roles at companies including Boston Biomedical, Apobiologix, Biothera Pharmaceuticals, Bionomics, Celgene, Abraxis BioScience, and Eli […]

Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects

Posted by |2020-03-05T16:40:18-08:00March 5th, 2020|

A 20-patient Phase 1 study of an RNA drug discovered by Ionis Pharmaceuticals that is being tested as a treatment for Huntington’s disease by Roche was suspended after two reports of infections related to a device used to take samples of cerebral spinal fluid during the trial. The suspension doesn’t appear to be related to […]

Melinta’s Chapter 11 Auction Draws No Bids, Deerfield to Get Assets

Posted by |2020-03-04T16:36:38-08:00March 4th, 2020|

The assets of Melinta Therapeutics will go to creditor Deerfield Management after no bidders for the company emerged, the antibiotics developer announced Wednesday. Under a court-approved Chapter 11 bankruptcy plan, any bids for the company were due by March 2. An auction was scheduled for March 6 in the event any bids were submitted. But […]

Court Rules More Trial Data Must Be Posted On

Posted by |2020-03-03T22:40:15-08:00March 3rd, 2020|

Plaintiff Peter Lurie, former US FDA associate commissioner, expects results of hundreds of clinical trials of approved drugs will become available under ruling against HHS; co-plaintiff sought eteplirsen study data. The results of potentially hundreds of clinical trials of approved drugs and medical devices will have to be published on the website in the […]

Gilead Boosts Cancer Drug Pipeline With $4.9B Deal for Forty Seven

Posted by |2020-03-02T16:48:19-08:00March 2nd, 2020|

Gilead Sciences, which finished 2019 with nearly $26 billion at its disposal, is putting some of that money to work with a $4.9 billion deal to acquire cancer immunotherapy developer Forty Seven. Under deal terms announced Monday, Foster City, CA-based Gilead (NASDAQ: GILD) will pay $95.50 for each share of Forty Seven (NASDAQ: FTSV). That’s […]
Go to Top